Selin Somersan-Karakaya, Kenneth C Turner, Luz Cortes-Burgos, Jutta Miller, Michael LaCroix-Fralish, Veronika Logovinsky, Yamini Patel, Richard Torres, Samit Ganguly, Aurora Breazna, Michelle DeVeaux, Rafia Bhore, Min Gao, Frank J Delfino, Ashique Rafique, Jeanette L Fairhurst, Charleen Hunt, Robert Babb, Ashok Badithe, William T Poueymirou, Ronald Surowitz, Sylvie Rottey, Andrew J Murphy, Olivier Harari, Lynn E Macdonald, Susan D Croll
The artemin-GFRα3 signaling pathway has been implicated in various painful conditions including migraine, cold allodynia, hyperalgesia, inflammatory bone pain, and mouse knees contain GFRα3-immunoreactive nerve endings. We developed high affinity mouse (REGN1967) and human (REGN5069) GFRα3-blocking monoclonal antibodies and, following in vivo evaluations in mouse models of chronic joint pain (osteoarthritic-like and inflammatory), conducted a first-in-human phase 1 pharmacokinetics (PK) and safety trial of REGN5069 (NCT03645746) in healthy volunteers, and a phase 2 randomized placebo-controlled efficacy and safety trial of REGN5069 (NCT03956550) in patients with knee osteoarthritis (OA) pain...
2023: Neurobiology of Pain